The establishment of EVISA is funded by the EU through
the Fifth Framework Programme (G7RT- CT- 2002- 05112).
Supporters of EVISA includes:
A synthetic ultrasmall superparamagnetic iron oxide composed of
dextran-coated iron oxide nanoparticles (also known as 'ultrasmall
particulate iron oxides' or USPIO). Ferumoxtran-10, which accumulates
in non-cancerous lymphatic tissue, is used as a molecular resonance
imaging (MRI) contrast agent.